959236-96-5

Usage

Uses

Used in Pharmaceutical Industry:
8-Fluoro-2,4(1H,3H)-quinazolinedione is used as a building block for the synthesis of various pharmaceutical compounds. Its unique chemical structure and properties make it suitable for the development of drugs with potential therapeutic applications.
Used in Drug Development:
8-Fluoro-2,4(1H,3H)-quinazolinedione is used as a key intermediate in the synthesis of pharmaceutical drugs. Its presence in the molecular structure can influence the drug's pharmacological properties, such as potency, selectivity, and bioavailability.
Used in Medicinal Chemistry Research:
8-Fluoro-2,4(1H,3H)-quinazolinedione is used as a starting material in medicinal chemistry research to explore its potential as a therapeutic agent or to modify its structure to develop new drugs with improved properties.
Used in Drug Design:
8-Fluoro-2,4(1H,3H)-quinazolinedione is used in drug design to create novel compounds with specific biological activities. Its unique structure can be exploited to design drugs that target specific receptors or enzymes, leading to the development of more effective and selective therapeutic agents.

Upstream product

• 590-28-3 potassium cyanate 
• 825-22-9 3-fluoroanthranilic acid 
• 57-13-6 urea 
• 124-38-9 carbon dioxide 
• 115661-37-5 2-amino-3-fluorobenzonitrile 

Downstream Products

• 1292802-72-2 2-N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-8-fluoro-4-N-(furan-2-ylmethyl)quinazoline-2,4-diamine 
• 1356349-42-2 N-[2-({[(2S)-1-cyclopentylpropan-2-yl]amino}methyl)-4-fluorophenyl]-8-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide 
• 1356349-83-1 tert-butyl [(2S)-1-cyclopentylpropan-2-yl](5-fluoro-2-{[(8-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)sulfonyl]amino}benzyl)carbamate 
• 139996-64-8 2-chloro-8-fluoro-N-methyl-N-phenylquinazolin-4-amine 
• 959237-64-0 2,4-dichloro-8-fluoroquinazoline 

Relevant academic research and scientific papers

Method for preparing 2,4-(1H,3H)-quinazoline diketone compound

The invention discloses a method for preparing a 2,4-(1H,3H)-quinazoline diketone compound. A 2-aminobenzonitrile compound as shown in a formula (1) and carbon dioxide are used as raw materials and react in 2-hydroxypyridine ionic liquid to obtain the 2,4-(1H,3H)-quinazoline diketone compound as shown in a formula (II), and the reaction formula is as shown in the specification. When the ionic liquid is applied to the reaction for preparing the 2,4-(1H,3H)-quinazoline diketone compound, the reaction condition is mild, the separation and purification process of the product is simple, the product yield is high, and the substrate application range is wide.

Facile and efficient synthesis of quinazoline-2,4(1H,3H)-diones through sequential hydrogenation condensation

The heterocyclizations from various methyl (2-nitrobenzoyl)carbamates to substituted quinazoline-2,4(1H,3H)-diones under hydrogenation conditions were investigated in this study. In the presence of p-toluenesulfonic acid monohydrate in methanol, various q

Synthesis and Characterization of Amidato Divalent Lanthanide Complexes and Their Use in Forming 2,4-Quinazolidinones from CO2 and 2-Aminobenzonitriles

Four amidato divalent lanthanide complexes, {LnLn[N(TMS)2]THF}2 [n = 1, Ln = Eu (1); n = 2, Ln = Eu (3), Yb (4); HL1 = tBuC6H4CONHC6H3(iPr)2; HL2 = C6H5CONHC6H3(iPr)2] and {L3Eu[N(TMS)2]THF}{L32Eu(THF)2} (2) [HL3 = ClC6H4CONHC6H3(iPr)2], were synthesized and extensively characterized. This is the first time that the amidato lanthanide amides 1-4 were used to catalyze the reactions of CO2 and 2-aminobenzonitriles to form quinazoline-2,4(1H,3H)-diones at atmospheric pressure. All the complexes efficiently catalyzed the transformation, with complex 3 showing the highest activity. This catalytic system gave good to excellent yields, and good functional group tolerance. Preliminary studies were conducted to investigate the reaction mechanism.

Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors

Poly(ADP-ribose)polymerase-1 (PARP-1) has emerged as a promising anticancer drug target due to its key role in the DNA repair process. In this work, a novel series of 1-benzyl-quinazoline-2,4(1H,3H)-dione derivatives were designed and synthesized as human PARP-1 inhibitors, structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values of single or double digit nanomolar level. Compound 7j was a potent PARP-1 and PARP-2 inhibitor and it could selectively kill the breast cancer cells MX-1 and MDA-MB-468 with mutated BRCA1/2 and PTEN, respectively, in comparison with homologous recombination proficient cell types such as breast cancer cells MDA-MB-231. In addition, compound 7j displayed the strongest potentiation effect on temozolomide in MX-1 cells (PF50 = 3.77) in this series of PARP-1 inhibitors.

HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF TRANSFER RNA SYNTHETASE FOR USE AS ANTIBACTERIAL AGENTS

The present invention provides aromatic sulphonamides as tRNA synthetase inhibitors and process for their synthesis, pharmaceutical composition and method for treatment. Compounds disclosed can be used as antibacterial agents for the treatment or prevention of conditions caused by or contributed by aerobic and anaerobic Gram-positive pathogens, more particularly against bacterium, for example Staphylococcus, Enterococci and Streptococci. Compounds disclosed are used in particular for the treatment of skin and soft tissue infection, Formula (I)

Synthesis and biological evaluation of 2,4-diaminoquinazoline derivatives as novel heat shock protein 90 inhibitors

Novel 2,4-diaminoquinazoline derivatives originating from a virtual screening approach were designed, synthesized and their biological activities as heat shock protein 90 (Hsp90) inhibitors were evaluated. The prepared compounds exhibited significant anti-proliferative activities against DU-145, HT-29, HCT-116, A375P and MCF-7 cancer cell lines. The selected compounds were tested against Her2, a client protein of Hsp90, and showed significant reduction in Her2 protein expression. Compound 6b was found the most potent, reduced Her2 protein expression levels and induced Hsp70 protein expression levels significantly.

Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 5. Substituted 2,4-Diaminoquinazolines and Thienopyrimidines

Quinazolines bearing a secondary 4-(arylamino) substituent demonstrate an SAR for inhibition of the gastric (H+/K+)-ATPase different from the previously described 3-acylquinolines, suggesting that, although these compounds are also K+-competitive, they probably bind to the enzyme in a different orientation.Compounds bearing a tertiary 4-(arylamino)substituent, however, in particular 4-(N-methylarylamino), appear to possess an SAR quite similar to the 3-acylquinolines.We show that this arises from the effect of the N-methylation, which is to orientate the 4-(arylamino) substituent syn to C5, analogous to the 3-acylquinolines.Compounds possessing both a 4-(N-methylarylamino) substituent and a 2-(arylamino) substituent proved to be very potent, K+-competitive inhibitors of K+-stimulated ATPase activity with Ki values down to 12 nM.Some compounds also proved to be effective inhibitors of stimulated acid secretion in both the rat and dog when dosed intravenously.However, although a number of these demonstrated activity after oral administration in the dog, the level and variability precluded further evaluation.